港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

維昇藥業-B

25.960

+1.0804.34%

成交量：2.32萬

成交額：57.23萬

市值：29.59億

市盈率：-13.34

高：25.980

開：24.120

低：24.000

收：24.880

52周最高：68.800

52周最低：24.000

股本：1.14億

香港流通股本：1.14億

量比：0.63

換手率：0.02%

股息：- -

股息率：- -

每股收益(LYR):-1.946

淨資產收益率：-57.66%

總資產收益率：-29.52%

市淨率：3.05

市盈率(LYR):-13.34

市銷率: 3098.50

資料載入中...

總覽公司新聞資訊公告

異動解讀 | 核心產品隆培生長激素獲批上市，維昇藥業-B盤中大漲5.28%

維升藥業-B(02561)發布年度業績研究及開發成本9348.4萬元按年增加3.27%

維昇藥業-B（02561）2月無新增發行或股份變動

維升藥業-B擬3月12日舉行董事會會議批准年度業績

每日沽空追蹤 | 維升藥業-B 03月02日沽空量成交400股，沽空比例為2.23%

兒童軟骨發育不全新藥獲批，維升藥業擁有大中華區權益

每日沽空追蹤 | 維升藥業-B 02月26日沽空量成交900股，沽空比例為6.21%

每日沽空追蹤 | 維升藥業-B 02月23日沽空量成交500股，沽空比例為1.96%

維升藥業-B02月11日主力淨流出36.2萬元散户資金買入

晶泰科技與維升藥業達成數千萬元關鍵合作，AI+機器人共拓內分泌藥物千億級藍海市場

維昇藥業（2561）2026年1月股份變動月報：股本維持不變

隆培生長激素獲批，維升藥業-B(02561)估值增長打上「強心針」

國內第四款長效生長激素獲批，如何攪動百億市場競爭格局？

維升藥業-B(02561)：注射用隆培生長激素的生物製品上市許可申請獲國家藥監局批准

維升藥業-B盤中異動大幅上漲5.25%報39.700港元

港股異動 | 維升藥業-B(02561)盤中升逾9% 核心產品隆培促生長素預計即將獲批

維升藥業-B01月14日主力淨流入15.9萬元散户資金拋售

每日沽空追蹤 | 維升藥業-B 01月13日沽空量成交100股，沽空比例為0.78%

每日沽空追蹤 | 維升藥業-B 01月12日沽空量成交300股，沽空比例為2.48%

每日沽空追蹤 | 維升藥業-B 01月09日沽空量成交400股，沽空比例為0.76%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02561/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02561","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"維昇藥業-B","latestPrice":25.96,"timestamp":1774339160923,"preClose":24.88,"halted":0,"volume":23200,"delay":0,"changeRate":0.043408360128617436,"floatShares":113999999,"shares":113999999,"eps":-1.946273,"marketStatus":"已收盤","change":1.08,"latestTime":"03-24 15:59:20","open":24.12,"high":25.98,"low":24,"amount":572332,"amplitude":0.079582,"askPrice":25.96,"askSize":900,"bidPrice":25.02,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-2.452961,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774402200000},"marketStatusCode":5,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":24.88,"openAndCloseTimeList":[[1774315800000,1774324800000],[1774328400000,1774339200000]],"volumeRatio":0.632497,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02561\",,,,,undefined,":{"symbol":"02561","floatShares":113999999,"roa":"-29.52%","roe":"-57.66%","lyrEps":-1.946273,"volumeRatio":0.632497,"shares":113999999,"dividePrice":0,"high":25.98,"amplitude":0.079582,"preClose":24.88,"low":24,"week52Low":24,"pbRate":"3.05","psRate":"3098.50","week52High":68.8,"institutionHeld":0,"latestPrice":25.96,"committee":-0.636364,"eps":-1.946273,"divideRate":0,"volume":23200,"delay":0,"ttmEps":-2.452961,"open":24.12,"prevYearClose":32.8,"prevWeekClose":26.02,"prevMonthClose":32.78,"prevQuarterClose":32.8,"fiveDayClose":30.04,"twentyDayClose":33.4,"sixtyDayClose":36.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02561\",params:#limit:5,,,undefined,":[{"date":"2026-03-12","symbol":"02561","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1773279000000,"name":null,"time":"","dateTimestamp":1773244800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02561\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02561\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1746288000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02561\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02561","date":"2026-03-23","current":-10.583128,"percent":1,"low":-30.760225,"twenty":-27.197912,"median":-19.806882,"eighty":-14.627967,"high":-10.597933,"avg":-20.939026,"sd":5.86475,"marketCap":2612931536},"quantilePoints":[{"date":"2025-04-03","current":-21.475965,"twenty":-22.637245,"median":-22.569747,"eighty":-22.098421,"marketCap":5724824916},{"date":"2025-04-11","current":-18.134639,"twenty":-22.558476,"median":-18.349759,"eighty":-18.045823,"marketCap":4802017317},{"date":"2025-04-17","current":-25.787715,"twenty":-25.955056,"median":-22.513392,"eighty":-18.141011,"marketCap":4682394110},{"date":"2025-04-25","current":-29.965674,"twenty":-27.695216,"median":-22.653961,"eighty":-18.190408,"marketCap":5445704099},{"date":"2025-05-02","current":-28.244363,"twenty":-27.861811,"median":-26.066617,"eighty":-18.349759,"marketCap":5143797909},{"date":"2025-05-09","current":-27.581562,"twenty":-28.248468,"median":-27.028836,"eighty":-20.850724,"marketCap":5058352761},{"date":"2025-05-16","current":-27.481285,"twenty":-28.307048,"median":-27.470681,"eighty":-22.305907,"marketCap":5081138134},{"date":"2025-05-23","current":-29.180898,"twenty":-28.483617,"median":-27.481285,"eighty":-22.603559,"marketCap":5411526040},{"date":"2025-05-30","current":-27.585218,"twenty":-28.483617,"median":-27.495492,"eighty":-22.648389,"marketCap":5138101566},{"date":"2025-06-06","current":-26.147365,"twenty":-28.307048,"median":-27.481285,"eighty":-24.987287,"marketCap":5212154028},{"date":"2025-06-13","current":-28.707887,"twenty":-28.307048,"median":-27.486097,"eighty":-25.744296,"marketCap":5724824916},{"date":"2025-06-20","current":-27.87701,"twenty":-28.483617,"median":-27.500076,"eighty":-26.010837,"marketCap":5548238276},{"date":"2025-06-27","current":-26.600431,"twenty":-28.46744,"median":-27.491566,"eighty":-26.131215,"marketCap":5308991862},{"date":"2025-07-04","current":-25.999842,"twenty":-28.345085,"median":-27.470681,"eighty":-26.039907,"marketCap":5189368655},{"date":"2025-07-11","current":-25.483255,"twenty":-28.252573,"median":-27.442177,"eighty":-25.700877,"marketCap":5081138134},{"date":"2025-07-18","current":-27.275886,"twenty":-28.168194,"median":-27.211053,"eighty":-25.700877,"marketCap":5434311412},{"date":"2025-07-25","current":-27.917728,"twenty":-28.10544,"median":-27.177054,"eighty":-25.808828,"marketCap":5582416336},{"date":"2025-08-01","current":-26.858726,"twenty":-28.252573,"median":-27.236899,"eighty":-25.835301,"marketCap":5337473578},{"date":"2025-08-08","current":-26.45431,"twenty":-28.168194,"median":-27.174901,"eighty":-25.937332,"marketCap":5270256728},{"date":"2025-08-15","current":-27.513449,"twenty":-28.142473,"median":-27.236899,"eighty":-26.012565,"marketCap":5473046546},{"date":"2025-08-22","current":-26.703746,"twenty":-28.118557,"median":-27.177054,"eighty":-26.021282,"marketCap":5295320638},{"date":"2025-08-29","current":-26.119434,"twenty":-28.10544,"median":-27.144467,"eighty":-26.021282,"marketCap":5204179147},{"date":"2025-09-05","current":-23.791598,"twenty":-28.093765,"median":-27.114576,"eighty":-25.835301,"marketCap":4735670561},{"date":"2025-09-12","current":-23.381705,"twenty":-28.083375,"median":-27.05699,"eighty":-25.694259,"marketCap":4662460107},{"date":"2025-09-19","current":-23.051901,"twenty":-28.060478,"median":-27.021811,"eighty":-25.478949,"marketCap":4593433106},{"date":"2025-09-26","current":-21.933119,"twenty":-28.003961,"median":-26.881441,"eighty":-23.835003,"marketCap":4359159651},{"date":"2025-10-03","current":-19.179371,"twenty":-27.951558,"median":-26.814509,"eighty":-23.612343,"marketCap":4545323379},{"date":"2025-10-10","current":-18.42629,"twenty":-27.909584,"median":-26.722604,"eighty":-23.450061,"marketCap":4360487033},{"date":"2025-10-17","current":-18.280755,"twenty":-27.87397,"median":-26.671617,"eighty":-23.093007,"marketCap":4322679342},{"date":"2025-10-24","current":-17.856771,"twenty":-27.855424,"median":-26.557884,"eighty":-22.535934,"marketCap":4223959260},{"date":"2025-10-31","current":-16.854881,"twenty":-27.829876,"median":-26.452186,"eighty":-21.933119,"marketCap":3992912259},{"date":"2025-11-07","current":-16.17341,"twenty":-27.822718,"median":-26.363703,"eighty":-19.806882,"marketCap":3829078931},{"date":"2025-11-14","current":-14.606062,"twenty":-27.750423,"median":-26.249352,"eighty":-18.799844,"marketCap":3467805439},{"date":"2025-11-21","current":-13.329485,"twenty":-27.732081,"median":-26.119434,"eighty":-18.28655,"marketCap":3163243483},{"date":"2025-11-28","current":-13.563448,"twenty":-27.641863,"median":-26.021242,"eighty":-18.15057,"marketCap":3230457156},{"date":"2025-12-05","current":-15.697088,"twenty":-27.585218,"median":-25.856964,"eighty":-18.047863,"marketCap":3745061840},{"date":"2025-12-12","current":-16.915932,"twenty":-27.581562,"median":-25.811068,"eighty":-17.856771,"marketCap":4043322514},{"date":"2025-12-19","current":-15.561133,"twenty":-27.572592,"median":-25.748021,"eighty":-17.298197,"marketCap":3728258422},{"date":"2025-12-24","current":-15.871137,"twenty":-27.537106,"median":-25.592118,"eighty":-16.909424,"marketCap":3814375940},{"date":"2026-01-02","current":-14.633696,"twenty":-27.513319,"median":-25.499704,"eighty":-16.617104,"marketCap":3530818257},{"date":"2026-01-09","current":-14.6234,"twenty":-27.507904,"median":-25.36554,"eighty":-16.251482,"marketCap":3537119539},{"date":"2026-01-16","current":-14.627967,"twenty":-27.496935,"median":-23.827768,"eighty":-15.946573,"marketCap":3549722103},{"date":"2026-01-23","current":-16.340142,"twenty":-27.491697,"median":-23.637534,"eighty":-15.766708,"marketCap":3961405850},{"date":"2026-01-30","current":-14.661628,"twenty":-27.487059,"median":-23.520828,"eighty":-15.582389,"marketCap":3570726376},{"date":"2026-02-06","current":-14.624534,"twenty":-27.472802,"median":-23.381705,"eighty":-15.41764,"marketCap":3570726376},{"date":"2026-02-13","current":-14.275853,"twenty":-27.453945,"median":-23.154666,"eighty":-15.203628,"marketCap":3505613130},{"date":"2026-02-20","current":-14.390669,"twenty":-27.447813,"median":-22.932516,"eighty":-15.172676,"marketCap":3528717830},{"date":"2026-02-27","current":-13.887168,"twenty":-27.442691,"median":-22.626101,"eighty":-15.007296,"marketCap":3442600311},{"date":"2026-03-06","current":-13.692525,"twenty":-27.436603,"median":-22.183333,"eighty":-14.876498,"marketCap":3366984929},{"date":"2026-03-13","current":-13.213121,"twenty":-27.307751,"median":-21.922595,"eighty":-14.759688,"marketCap":3264063993},{"date":"2026-03-20","current":-11.103996,"twenty":-27.213507,"median":-20.641424,"eighty":-14.63255,"marketCap":2732655891},{"date":"2026-03-23","current":-10.597933,"twenty":-27.197912,"median":-19.806882,"eighty":-14.627967,"marketCap":2612931536}],"updateTime":1774345873399},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02561\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1142764103","title":"異動解讀 | 核心產品隆培生長激素獲批上市，維昇藥業-B盤中大漲5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142764103","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142764103?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 09:35","pubTimestamp":1773365728,"startTime":"0","endTime":"0","summary":"维昇药业-B(02561)今日盘中大涨5.28%，引起了市场的广泛关注。消息面上，公司核心产品注射用隆培生长激素（商品名：维臻高®/SKYTROFA®）已获得国家药品监督管理局的上市批准，用于治疗3岁及以上儿童及青少年的生长激素缺乏症。该产品是唯一一款在与短效人生长激素的对照试验中显示出长高疗效优效性的长效生长激素，其获批标志着公司进入了新的商业化阶段。此外，公司已建立专业的商业化团队，并计划于2026年全面启动该产品的商业化。尽管公司同期发布的年度业绩显示亏损有所扩大，但市场显然更聚焦于核心产品获批这一重大里程碑所带来的长期增长潜力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02561"],"gpt_icon":0},{"id":"2618130259","title":"維升藥業-B(02561)發布年度業績 研究及開發成本9348.4萬元 按年增加3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130259?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 22:45","pubTimestamp":1773326713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布截至2025年12月31日止年度业绩，期内取得收入16.5万元，其他收入1194.1万元;研究及开发成本9348.4万元，同比增加3.27%。针头的进口医疗器械注册申请已于2025年4月23日获得批准;自动注射器已于2024年4月获得批准。于2025年6月12日，公司与Ascendis Pharma订立商业化供应框架协议，进一步加强核心产品的供应安排。截至本公告日期，公司已建立一支精简但高度专业化的内部商业化团队，已完全具备核心学术推广及医学相关职能。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"1132808696","title":"維昇藥業-B（02561）2月無新增發行或股份變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1132808696","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132808696?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:10","pubTimestamp":1772615442,"startTime":"0","endTime":"0","summary":"维昇药业-B（02561）于2026年3月4日披露截至2026年2月28日的股份变动月报表。报告显示，公司法定/注册股本维持在500,000,000股，面值为每股0.0001美元，注册股本总额约50,000美元，与上月持平。\n截至本月末，公司已发行普通股总数为113,926,864股，较上月底无变化。当月未发生任何新增发行、回购或注销行为，亦无股份期权或股权激励计划导致的股份变动。公司同时确认满足香港联交所上市规则所要求的公众持股量规定。\n本次月报显示，公司整体股本结构保持稳定。公告由执行董事卢安邦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2616970391","title":"維升藥業-B擬3月12日舉行董事會會議批准年度業績","url":"https://stock-news.laohu8.com/highlight/detail?id=2616970391","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616970391?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 17:19","pubTimestamp":1772443193,"startTime":"0","endTime":"0","summary":"来源：格隆汇APP格隆汇3月2日丨维升药业-B(02561.HK)发布公告，董事会谨定于2026年3月12日（星期四）举行董事会会议，藉以（其中包括）考虑及批准本集团截至2025年12月31日止的年度业绩及其刊发，以及处理其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302172330a44188fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302172330a44188fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2616391909","title":"每日沽空追蹤 | 維升藥業-B 03月02日沽空量成交400股，沽空比例為2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616391909","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616391909?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 16:30","pubTimestamp":1772440234,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间03月02日，跌3.9%，卖空量成交400股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163458a730c7cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163458a730c7cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2616810145","title":"兒童軟骨發育不全新藥獲批，維升藥業擁有大中華區權益","url":"https://stock-news.laohu8.com/highlight/detail?id=2616810145","media":"医药时间","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616810145?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 19:58","pubTimestamp":1772279913,"startTime":"0","endTime":"0","summary":"维升药业拥有那韦培肽在大中华区的独家开发、生产及商业化权利。此次批准是基于三项随机、双盲、安慰剂对照临床试验，以及长达三年的开放标签扩展研究数据，其中包括在软骨发育不全患儿中开展的关键性 ApproaCH 试验结果。在中国，软骨发育不全症已被纳入《第二批罕见病目录》，但目前国内尚无切实有效的治疗方法。在此背景下，那韦培肽有望填补治疗空白，改变中国软骨发育不全症的治疗格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228213302a72abaad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228213302a72abaad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2614008547","title":"每日沽空追蹤 | 維升藥業-B 02月26日沽空量成交900股，沽空比例為6.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614008547","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614008547?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 16:30","pubTimestamp":1772094632,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间02月26日，跌0.36%，卖空量成交900股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163442a4cab5e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226163442a4cab5e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2613753492","title":"每日沽空追蹤 | 維升藥業-B 02月23日沽空量成交500股，沽空比例為1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613753492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613753492?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 16:30","pubTimestamp":1771835431,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间02月23日，跌1.79%，卖空量成交500股，较上一交易日增加100%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163405a71564c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163405a71564c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2610937738","title":"維升藥業-B02月11日主力淨流出36.2萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937738?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 16:16","pubTimestamp":1770797761,"startTime":"0","endTime":"0","summary":"02月11日, 维升药业-B股价跌0.60%，报收33.30元，成交金额113.0万元，换手率0.03%，振幅2.63%，量比3.25。维升药业-B今日主力资金净流出36.2万元，上一交易日主力净流出0万元。该股近5个交易日下跌0.54%，主力资金累计净流出36.2万元；近20日主力资金累计净流出218.9万元，其中净流出天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162219a497233b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211162219a497233b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2610937768","title":"晶泰科技與維升藥業達成數千萬元關鍵合作，AI+機器人共拓內分泌藥物千億級藍海市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2610937768","media":"医药健闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610937768?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 11:58","pubTimestamp":1770782302,"startTime":"0","endTime":"0","summary":"美通社消息，以 AI+机器人驱动新药与新材料研发的创新平台晶泰科技与专注于内分泌领域的创新药企维升药业共同宣布达成项目协议及长期战略合作，本次合作整体规模达数千万元，围绕研发阶段目标，结合关键里程碑有序推进。晶泰科技拥有行业领先的 AI+机器人药物研发平台，已与全球数百家药企与前沿科研机构建立深度合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211122818a49655c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260211122818a49655c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1617","02228","BK1141","BK1161"],"gpt_icon":0},{"id":"1126602143","title":"維昇藥業（2561）2026年1月股份變動月報：股本維持不變","url":"https://stock-news.laohu8.com/highlight/detail?id=1126602143","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126602143?lang=zh_tw&edition=fundamental","pubTime":"2026-02-03 16:37","pubTimestamp":1770107820,"startTime":"0","endTime":"0","summary":"维昇药业（股票代码：2561）于2026年2月3日发布2026年1月股份变动月报。公告显示，截至1月31日，公司普通股注册股本维持在500,000,000股，面值每股USD 0.0001，注册股本总额USD 50,000。期末已发行普通股数量为113,926,864股，较上月底无新增发行或注销，库藏股数为零。\n报告期内，公司并无股份期权或可换股债券行使，无购回或注销记录。董事会确认公司公众持股量符合香港联交所相关要求。公告由执行董事卢安邦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c948fb8095e6dfc21c5f65a8776294af","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"gpt_icon":0},{"id":"2606209220","title":"隆培生長激素獲批，維升藥業-B(02561)估值增長打上「強心針」","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209220","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606209220?lang=zh_tw&edition=fundamental","pubTime":"2026-01-27 08:52","pubTimestamp":1769475131,"startTime":"0","endTime":"0","summary":"1月26日，港股创新药企维升药业-B给出了答案：其核心产品隆培生长激素于近日正式获国家药监局上市批准。目前，维升药业已在中国完成其用于治疗3至17岁儿童生长激素缺乏症的3期关键性试验。伴随隆培生长激素未来获批上市及其他在研管线向前推进，公司将进入全面加速发展的新阶段，步入收获期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"隆培生长激素获批，维升药业-B(02561)估值增长打上“强心针”","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606335223","title":"國內第四款長效生長激素獲批，如何攪動百億市場競爭格局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2606335223","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606335223?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 22:32","pubTimestamp":1769437951,"startTime":"0","endTime":"0","summary":"国内生长激素领域又迎来新选手。这是国内获批的第四款长效生长激素，也是国内首个且目前唯一经三期临床证实优效于日制剂的长效生长激素。此外，国内长效生长激素市场规模预计将在两年内超过短效产品，并在2030年占据全市场80%的份额。此次隆培生长激素在国内获批是基于一项3期关键性试验。维升药业相关负责人认为，真正使用生长激素的患者，绝大多数仍然是自费，早已进入医保的短效生长激素就是如此。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126223623a4581e52&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126223623a4581e52&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606211537","title":"維升藥業-B(02561)：注射用隆培生長激素的生物製品上市許可申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2606211537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606211537?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 18:45","pubTimestamp":1769424332,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B 发布公告，中国国家药品监督管理局已批准注射用隆培生长激素的生物制品上市许可申请，用于在中国治疗3岁及以上儿童及青少年的生长激素缺乏症所致的生长缓慢。此新药获批上市主要依据于中国完成对3至17岁儿童生长激素缺乏症患者的3期关键性试验。隆培生长激素获BLA批准后，集团已启动全面商业化计划，以确保供应并扩大市场覆盖。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维升药业-B(02561)：注射用隆培生长激素的生物制品上市许可申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2606238102","title":"維升藥業-B盤中異動 大幅上漲5.25%報39.700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606238102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606238102?lang=zh_tw&edition=fundamental","pubTime":"2026-01-26 15:52","pubTimestamp":1769413972,"startTime":"0","endTime":"0","summary":"2026年01月26日临近收盘15时52分，维升药业-B股票出现异动，股价快速拉升5.25%。截至发稿，该股报39.700港元/股，成交量2.9万股，换手率0.03%，振幅5.25%。资金方面，该股资金流入83.2472万港元，流出19.8304万港元。维升药业-B股票所在的生物技术行业中，整体跌幅为2.15%。其相关个股中，北海康成-B、维亚生物、中生北控生物科技涨幅较大，振幅较大的相关个股有北海康成-B、中生北控生物科技、维亚生物，振幅分别为19.48%、17.28%、15.35%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126155252a4569304&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260126155252a4569304&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2605342821","title":"港股異動 | 維升藥業-B(02561)盤中升逾9% 核心產品隆培促生長素預計即將獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2605342821","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605342821?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 11:52","pubTimestamp":1769140357,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B(02561)盘中涨超9%，截至发稿，涨7.13%，报37.24港元。消息面上，据Insight数据库显示，维升药业-B核心产品隆培促生长素已于2026年1月12日离开补充资料任务，预计即将获批。据公开资料显示，隆培促生长素是维升药业-B从Ascendis Pharma引进的长效生长激素前药，基于TransCon暂时连接技术研发，用于治疗儿童生长激素缺乏症(GHD)，每周皮下注射一次，可释放未经修饰的天然人生长激素，欧美此前已获批。国内生长激素市场以日制剂为主，周制剂可大幅提升患者依从性，上市后有望重塑竞争格局，满足未被充分满足的临床需求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 维升药业-B(02561)盘中涨超9% 核心产品隆培促生长素预计即将获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561","BK1610"],"gpt_icon":0},{"id":"2603661929","title":"維升藥業-B01月14日主力淨流入15.9萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603661929","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603661929?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 16:16","pubTimestamp":1768378573,"startTime":"0","endTime":"0","summary":"01月14日, 维升药业-B股价涨2.27%，报收34.28元，成交金额115.2万元，换手率0.03%，振幅5.67%，量比1.16。维升药业-B今日主力资金净流入15.9万元，上一交易日主力净流出0万元。该股近5个交易日下跌2.00%，主力资金累计净流入77.4万元；近20日主力资金累计净流出74.4万元，其中净流出天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114162621a4c25e56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260114162621a4c25e56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2603468687","title":"每日沽空追蹤 | 維升藥業-B 01月13日沽空量成交100股，沽空比例為0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603468687","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603468687?lang=zh_tw&edition=fundamental","pubTime":"2026-01-13 16:30","pubTimestamp":1768293031,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月13日，涨0.18%，卖空量成交100股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164444a714fd85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113164444a714fd85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0},{"id":"2602548248","title":"每日沽空追蹤 | 維升藥業-B 01月12日沽空量成交300股，沽空比例為2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602548248","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602548248?lang=zh_tw&edition=fundamental","pubTime":"2026-01-12 16:30","pubTimestamp":1768206630,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月12日，跌0.65%，卖空量成交300股，较上一交易日减少66.67%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164944a710ca0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112164944a710ca0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02561","BK1161"],"gpt_icon":0},{"id":"2602373703","title":"每日沽空追蹤 | 維升藥業-B 01月09日沽空量成交400股，沽空比例為0.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373703","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602373703?lang=zh_tw&edition=fundamental","pubTime":"2026-01-09 16:30","pubTimestamp":1767947431,"startTime":"0","endTime":"0","summary":"维升药业-B北京时间01月09日，跌0.24%，卖空量成交400股，较上一交易日减少55.56%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163840a7067e50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109163840a7067e50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02561"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":66,"code":"91000000","status":"200"}]}}